NCT00411294

Brief Summary

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 11, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 13, 2006

Completed
Last Updated

December 13, 2006

Status Verified

December 1, 2006

First QC Date

December 11, 2006

Last Update Submit

December 11, 2006

Conditions

Chronic Kidney Disease

Keywords

ergocalciferolchronic kidney diseasesecondary hyperparathyroidismvitamin D deficiency

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels \>70 pg/ml.

You may not qualify if:

  • Patients who are on any form of active vitamin treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saint Louis VA Medical Center

St Louis, Missouri, 63104, United States

Location

Related Publications (1)

  • Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59-68. doi: 10.1053/j.ajkd.2007.04.010.

    PMID: 17591525DERIVED

MeSH Terms

Conditions

Renal Insufficiency, ChronicHyperparathyroidism, SecondaryVitamin D Deficiency

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHyperparathyroidismParathyroid DiseasesEndocrine System DiseasesAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Ziyad Al-Aly, M.D.

    VAMC-Saint Louis

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
RETROSPECTIVE
Sponsor Type
FED

Study Record Dates

First Submitted

December 11, 2006

First Posted

December 13, 2006

Last Updated

December 13, 2006

Record last verified: 2006-12

Locations

US(1)